Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Crohns Colitis ; 9(5): 382-9, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25740813

RESUMO

BACKGROUND AND AIMS: Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe the clinical course of CVA in these patients. METHODS: This was a European Crohn's and Colitis Organisation [ECCO] retrospective observational study, performed as part of the CONFER [COllaborative Network For Exceptionally Rare case reports] project. A call to all ECCO members was made to report on IBD patients afflicted with CVA during treatment with anti-TNF alpha agents. Clinical data were recorded in a standardised case report form and analysed for event association with anti-TNF alpha treatment. RESULTS: A total of 19 patients were identified from 16 centres: 14 had Crohn's disease, four ulcerative colitis and one IBD colitis unclassified [median age at diagnosis: 38.0 years, range: 18.6-62.5]. Patients received anti-TNF alpha for a median duration of 11.8 months [range: 0-62] at CVA onset; seven had previously been treated with at least one other anti-TNF alpha agent. Complete neurological recovery was observed in 16 patients. Anti-TNF alpha was discontinued in 16/19 patients. However, recurrent CVA or neurological deterioration was not observed in any of the 11 patients who received anti-TNF alpha after CVA [eight resumed after temporary cessation, three continued without interruption] for a median follow-up of 39.8 months [range: 5.6-98.2]. CONCLUSION: These preliminary findings do not unequivocally indicate a causal role of anti-TNF alpha in CVA complicating IBD. Resuming or continuing anti-TNF alpha in IBD patients with CVA may be feasible and safe in selected cases, but careful weighing of IBD activity versus neurological status is prudent.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Transtornos Cerebrovasculares/etiologia , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Imunossupressores/uso terapêutico , Doenças Raras/etiologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab/uso terapêutico , Adulto , Azatioprina/uso terapêutico , Transtornos Cerebrovasculares/diagnóstico , Certolizumab Pegol/uso terapêutico , Colite Ulcerativa/complicações , Doença de Crohn/complicações , Quimioterapia Combinada , Feminino , Humanos , Infliximab/uso terapêutico , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Doenças Raras/diagnóstico , Retratamento , Estudos Retrospectivos , Adulto Jovem
2.
Sci Rep ; 4: 4887, 2014 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-24811607

RESUMO

The exact treatment of Markovian open quantum systems, when based on numerical diagonalization of the Liouville super-operator or averaging over quantum trajectories, is severely limited by Hilbert space size. Perturbation theory, standard in the investigation of closed quantum systems, has remained much less developed for open quantum systems where a direct application to the Lindblad master equation is desirable. We present such a perturbative treatment which will be useful for an analytical understanding of open quantum systems and for numerical calculation of system observables which would otherwise be impractical.

3.
Hepatogastroenterology ; 52(62): 469-70, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15816459

RESUMO

A 29-year-old female presented with anorexia, vomiting and weight loss. A diagnosis of superior mesenteric artery syndrome was made based upon contrast duodenography and then at laparotomy when the patient was successfully treated with a duodenojejunostomy. Superior mesenteric artery syndrome is a rare cause of vomiting not detectable by endoscopy, but is eminently amenable to treatment.


Assuntos
Síndrome da Artéria Mesentérica Superior/complicações , Vômito/etiologia , Adulto , Bário , Técnicas de Diagnóstico por Cirurgia , Duodenostomia , Duodeno/diagnóstico por imagem , Feminino , Humanos , Jejunostomia , Radiografia Abdominal , Síndrome da Artéria Mesentérica Superior/diagnóstico por imagem , Síndrome da Artéria Mesentérica Superior/cirurgia , Tomografia Computadorizada por Raios X
5.
Eur J Gastroenterol Hepatol ; 15(2): 185-7, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12560764

RESUMO

Azathioprine is now widely used for the maintenance treatment of Crohn's disease, but there are concerns whether azathioprine could predispose to malignancy in patients with inflammatory bowel disease. We report here a case of a 39-year-old non-smoking male with Crohn's disease who had been treated for 3 years with azathioprine and developed a lingual ulcer. Biopsy revealed squamous cell carcinoma, a tumour not previously associated with Crohn's disease.


Assuntos
Antimetabólitos/efeitos adversos , Azatioprina/efeitos adversos , Carcinoma in Situ/induzido quimicamente , Doença de Crohn/tratamento farmacológico , Neoplasias da Língua/induzido quimicamente , Adulto , Carcinoma in Situ/patologia , Doença de Crohn/patologia , Humanos , Masculino , Mucosa Bucal/efeitos dos fármacos , Neoplasias da Língua/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA